Arcutis Biotherapeutics Inc. (ARQT)
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ARQT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.04B
- P/E (TTM)
- 109.86
- Forward P/E
- 17.77
- EPS (TTM)
- $0.22
- Dividend yield
- None
- 52-week range
- 19.30 – 31.77
- Day range
- 23.51 – 24.38
- Volume / Avg
- 1.70M / 2.22M
- Beta
- —
- Shares outstanding
- 125.69M
- Next earnings
- Oct 27, 2026
52-week range
ARQT stock today
Arcutis Biotherapeutics (ARQT) closed at $24.17 on Oct 7, up 1.05% (+$0.25), versus the S&P 500's 0.22% decline. At this level, ARQT sits in the middle of its 52-week range of $19.30 to $31.77: 23.9% below the high, set on Dec 8, 2025 and 25.3% above the low. ARQT is down 16.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 17.5%.
Arcutis Biotherapeutics trades at 109.9x its trailing twelve-month earnings per share of $0.22. Its forward P/E of 17.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of $0.17.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcutis Biotherapeutics
Company profileArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Todd Franklin Watanabe M.A.
- Headquarters
- Westlake Village, CA
- Employees
- 354
- IPO year
- 2020
- Website
- arcutis.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$37.00+53.08%
- Strong buy 2
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $0.17
ARQT news
All ARQT newsArcutis Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs ARQT |
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs ARQT |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs ARQT |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs ARQT |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs ARQT |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs ARQT |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs ARQT |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs ARQT |
Indexes, lists and sector
Arcutis Biotherapeutics stock FAQ
What is Arcutis Biotherapeutics's stock price today?
ARQT last traded at $24.17 as of Oct 7, 4:00 PM EDT, up 1.05% on the day. Prices are delayed at least 15 minutes.
When is Arcutis Biotherapeutics's next earnings date?
Arcutis Biotherapeutics is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $0.17.
What is ARQT's P/E ratio?
ARQT trades at a trailing P/E ratio of 109.86 and a forward P/E of 17.77.
Who is Arcutis Biotherapeutics's CEO?
Mr. Todd Franklin Watanabe M.A. is the chief executive officer of Arcutis Biotherapeutics Inc., which has about 354 employees.
What is the ARQT 52-week high?
The 52-week high for ARQT is $31.77 and the 52-week low is $19.30. The stock is currently 23.9% below its high.